![Daqing Cai](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Daqing Cai
Director/Miembro de la Junta en Beijing Shenogen Pharma Group Ltd. .
Perfil
Daqing Cai is currently a Director at Appia Bio, Inc. and Beijing Shenogen Pharma Group Ltd.
Previously, he held the position of Managing Director at Legend Capital Co. Ltd.
from 2015 to 2018.
He also served as an Independent Director at Bionano Genomics, Inc. from 2014 to 2019.
Additionally, he has held director positions at Innovent Biologics, Inc., Indi Molecular, Inc., and Axonics, Inc. Dr. Cai was also the Chief Financial Officer & Director at Beijing Genomics Institute from 2014 to 2016.
He holds an MBA from Yale University, a doctorate from the University of California, Berkeley, and an undergraduate degree from the University of Science & Technology of China.
Cargos activos de Daqing Cai
Empresas | Cargo | Inicio |
---|---|---|
Beijing Shenogen Pharma Group Ltd.
![]() Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Director/Miembro de la Junta | - |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Daqing Cai.
Empresas | Cargo | Fin |
---|---|---|
BIONANO GENOMICS, INC. | Director/Miembro de la Junta | 21/08/2019 |
Legend Capital Co. Ltd.
![]() Legend Capital Co. Ltd. Investment ManagersFinance Legend Capital Co. Ltd (Legend Capital) is a private equity venture capital subsidiary of Legend Holdings Corp. founded in 2001 by Zhu Li Nan. The firm is headquartered in Beijing, China. | Corporate Officer/Principal | 01/04/2018 |
Beijing Genomics Institute
![]() Beijing Genomics Institute BiotechnologyHealth Technology Part of BGI Genomics Co., Ltd., Beijing Genomics Institute develops science and technology services in the genomics field. The company is based in Shenzhen, China. | Director Financiero/CFO | 01/01/2016 |
Indi Molecular, Inc.
![]() Indi Molecular, Inc. BiotechnologyHealth Technology Indi Molecular, Inc. is a life sciences company that develops a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. It offers products used by physicians and patients to manage complex and serious diseases like cancer, diabetes, and Alzheimer's. The company was founded by Michael Phelps, Albert A. Luderer, Leroy E. Hood, and Jim Heath in 2013 and is headquartered in Culver City, CA. | Director/Miembro de la Junta | - |
INNOVENT BIOLOGICS, INC. | Director/Miembro de la Junta | - |
Formación de Daqing Cai.
University of Science & Technology of China | Undergraduate Degree |
Yale University | Masters Business Admin |
University of California, Berkeley | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
BIONANO GENOMICS, INC. | Health Technology |
AXONICS, INC. | Health Technology |
INNOVENT BIOLOGICS, INC. | Health Technology |
Empresas privadas | 5 |
---|---|
Beijing Genomics Institute
![]() Beijing Genomics Institute BiotechnologyHealth Technology Part of BGI Genomics Co., Ltd., Beijing Genomics Institute develops science and technology services in the genomics field. The company is based in Shenzhen, China. | Health Technology |
Legend Capital Co. Ltd.
![]() Legend Capital Co. Ltd. Investment ManagersFinance Legend Capital Co. Ltd (Legend Capital) is a private equity venture capital subsidiary of Legend Holdings Corp. founded in 2001 by Zhu Li Nan. The firm is headquartered in Beijing, China. | Finance |
Beijing Shenogen Pharma Group Ltd.
![]() Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Health Technology |
Indi Molecular, Inc.
![]() Indi Molecular, Inc. BiotechnologyHealth Technology Indi Molecular, Inc. is a life sciences company that develops a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. It offers products used by physicians and patients to manage complex and serious diseases like cancer, diabetes, and Alzheimer's. The company was founded by Michael Phelps, Albert A. Luderer, Leroy E. Hood, and Jim Heath in 2013 and is headquartered in Culver City, CA. | Health Technology |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
- Bolsa de valores
- Insiders
- Daqing Cai